Clinical Trials

9 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05755854 2023-09-22

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

10 enrolled

Hematologic Diseases

NCT04825496 2023-09-21

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05005299 2023-08-01

VICTORY

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05798546 2023-04-04

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

21 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

33 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

25 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05665075 2023-01-03

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

19 enrolled

Leukemia, Myeloid, Acute

NCT05665114 2023-01-03

Natural Killer(NK) Cell Therapy in r/r AML

Leukemia, Myeloid, Acute

NCT05640713 2022-12-07

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

12 enrolled

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

NCT01946373 2022-10-04

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Dermatologic

Melanoma

NCT05122221 2022-06-28

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

GastrointestinalGynecologicHead & Neck

12 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

NCT05379647 2022-05-18

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

24 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04823091 2022-03-16

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

24 enrolled

Leukemia, T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell

NCT05008575 2022-01-12

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

27 enrolled

Leukemia, Myeloid, Acute

NCT04796675 2021-04-08

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

27 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04653493 2021-03-19

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

22 enrolled

Burkitt Lymphoma

NCT04796688 2021-03-15

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03716856 2020-10-08

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

11 enrolled

Plasma cell

Multiple Myeloma

NCT04221971 2020-10-01

NK Cell Infusion for Patients With Acute Myeloid Leukemia

10 enrolled

Leukemia, Myeloid, Acute

NCT03110640 2019-11-27

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT04037566 2019-07-30

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

40 enrolled

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03093168 2019-02-27

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

10 enrolled

Plasma cell

Multiple Myeloma

NCT03029273 2019-01-17

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Thoracic

Lung Neoplasms, Recurrence

NCT02366546 2018-10-24

Investigator Initiated Phase 1 Study of TBI-1301

DermatologicGastrointestinalGynecologicHead & NeckSarcoma

9 enrolled

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT03528421 2018-07-16

Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

30 enrolled

Lymphoma, Non-Hodgkin

NCT02924753 2017-12-29

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Burkitt Lymphoma

NCT03344705 2017-11-17

Safety and Efficacy Evaluation of IM19 Cells

Hematologic Neoplasms

NCT03208556 2017-09-14

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Recurrence, Lymphoma, B-Cell

NCT03101709 2017-04-05

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

30 enrolled

Lymphoma, B-Cell

NCT02937844 2016-10-19

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

CNS

Glioblastoma

NCT02933775 2016-10-14

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

45 enrolled

Lymphoma

NCT02456350 2016-08-03

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

36 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

36 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02844062 2016-07-26

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

CNS

Glioblastoma

NCT00625430 2011-07-11

FP253-GDEPT